Editas Medicine has appointed John Mendlein to its board of directors.
Mendlein is CEO of aTyr Pharma. He also serves on the boards of Fate Therapeutics (as vice chairman), Moderna Therapeutics, Pronutria Biosciences, and the emerging companies board of Biotechnology Industry Organization.
Prior to joining aTyr, he served as CEO of both Adnexus Therapeutics and Affinium Pharmaceuticals.
Mendlein holds a PhD in physiology and biophysics from the University of California, Los Angeles, a JD from the University of California, Hastings College of the Law and a BS in biology from the University of Miami.